The results showed high efficacy in treating patients with newly diagnosed FLT3-mutated AML, showing an ORR of 96% (CR, 88%) and an OS rate of 88%, with a median follow-up of 6.2 months (Table 1) [50]. This evidence concerns the gene FLT3 and acute myeloid leukemia.